First Light Asset Management LLC Buys Shares of 201,867 Enliven Therapeutics, Inc. $ELVN

First Light Asset Management LLC bought a new stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 201,867 shares of the company’s stock, valued at approximately $7,913,000.

A number of other hedge funds have also made changes to their positions in the stock. SummitTX Capital L.P. acquired a new stake in shares of Enliven Therapeutics during the first quarter worth approximately $2,693,000. Affinity Asset Advisors LLC acquired a new position in Enliven Therapeutics in the 1st quarter valued at approximately $23,007,000. Entropy Technologies LP acquired a new position in Enliven Therapeutics in the 1st quarter valued at approximately $239,000. Siren L.L.C. purchased a new stake in Enliven Therapeutics in the 1st quarter worth approximately $29,252,000. Finally, Walleye Capital LLC purchased a new stake in Enliven Therapeutics in the 1st quarter worth approximately $1,483,000. 95.08% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Enliven Therapeutics

In other Enliven Therapeutics news, Director Lori Anne Kunkel sold 10,000 shares of the business’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $34.54, for a total transaction of $345,400.00. Following the completion of the transaction, the director owned 51,884 shares of the company’s stock, valued at $1,792,073.36. The trade was a 16.16% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Benjamin Hohl sold 6,018 shares of the business’s stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $43.80, for a total transaction of $263,588.40. Following the transaction, the chief financial officer directly owned 51,000 shares of the company’s stock, valued at approximately $2,233,800. This represents a 10.55% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 26,018 shares of company stock worth $1,113,888 in the last quarter. Insiders own 3.00% of the company’s stock.

Analysts Set New Price Targets

ELVN has been the topic of several research analyst reports. The Goldman Sachs Group boosted their price target on shares of Enliven Therapeutics from $59.00 to $67.00 and gave the company a “buy” rating in a report on Tuesday, July 21st. JonesTrading increased their price objective on Enliven Therapeutics from $45.00 to $70.00 and gave the stock a “buy” rating in a report on Monday, June 29th. Wall Street Zen raised Enliven Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, May 11th. Guggenheim initiated coverage on Enliven Therapeutics in a research note on Tuesday, May 12th. They issued a “buy” rating and a $80.00 target price on the stock. Finally, HC Wainwright upped their price objective on shares of Enliven Therapeutics from $56.00 to $64.00 and gave the stock a “buy” rating in a report on Thursday, July 9th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $70.50.

Enliven Therapeutics Price Performance

Shares of ELVN stock opened at $52.95 on Monday. Enliven Therapeutics, Inc. has a 12 month low of $14.78 and a 12 month high of $54.88. The company has a market cap of $3.22 billion, a PE ratio of -31.71 and a beta of 0.24. The business’s 50 day moving average is $45.49 and its two-hundred day moving average is $37.43.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.38) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.06. As a group, equities analysts expect that Enliven Therapeutics, Inc. will post -1.57 EPS for the current fiscal year.

Enliven Therapeutics Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.